Genetic testing for cancer predisposition

被引:75
作者
Eng, C [1 ]
Hampel, H
de la Chapelle, A
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA
来源
ANNUAL REVIEW OF MEDICINE | 2001年 / 52卷
关键词
inherited neoplasia syndrome; mutation; predictive testing;
D O I
10.1146/annurev.med.52.1.371
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Clinical cancer genetics is becoming an integral part of the care of cancer patients. This review describes the clinical aspects, genetics, and clinical genetic management of most of the major hereditary cancer susceptibility syndromes. Multiple endocrine neoplasia type 2, von Hippel-Lindau disease, and familial adenomatous polyposis are examples of syndromes for which genetic testing to identify at-risk family members is considered the standard of care. Genetic testing for these syndromes is sensitive and affordable, and it will change medical management. Cancer genetic counseling and testing is probably beneficial in other syndromes, such as the hereditary breast cancer syndromes, hereditary nonpolyposis colorectal cancer syndrome, Peutz-Jeghers syndrome, and juvenile polyposis. There are also hereditary cancer syndromes for which testing is not yet available and/or is unlikely to change medical management, including Li-Fraumeni syndrome and hereditary malignant melanoma. Thorough medical care requires the identification of families likely to have a hereditary cancer susceptibility syndrome for referral to cancer genetics professionals.
引用
收藏
页码:371 / 400
页数:30
相关论文
共 81 条
  • [1] Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
    Aaltonen, LA
    Salovaara, R
    Kristo, P
    Canzian, F
    Hemminki, A
    Peltomäki, P
    Chadwick, RB
    Kääriäinen, H
    Eskelinen, M
    Järvinen, H
    Mecklin, JP
    de la Chapelle, A
    Percesepe, A
    Ahtola, H
    Härkönen, N
    Julkunen, R
    Kangas, E
    Ojala, S
    Tulikoura, J
    ValKamo, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) : 1481 - 1487
  • [2] Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO
  • [3] 2-C
  • [4] Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma
    Baysal, BE
    Ferrell, RE
    Willett-Brozick, JE
    Lawrence, EC
    Myssiorek, D
    Bosch, A
    van der Mey, A
    Taschner, PEM
    Rubinstein, WS
    Myers, EN
    Richard, CW
    Cornelisse, CJ
    Devilee, P
    Devlin, B
    [J]. SCIENCE, 2000, 287 (5454) : 848 - 851
  • [5] Increased risk for cancer in patients with the Peutz-Jeghers syndrome
    Boardman, LA
    Thibodeau, SN
    Schaid, DJ
    Lindor, NM
    McDonnell, SK
    Burgart, LJ
    Ahlquist, DA
    Podratz, KC
    Pittelkow, M
    Hartmann, LC
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (11) : 896 - +
  • [6] FAMILIAL MULTIPLE ENDOCRINE NEOPLASIA TYPE-I - A NEW LOOK AT PATHOPHYSIOLOGY
    BRANDI, ML
    MARX, SJ
    AURBACH, GD
    FITZPATRICK, LA
    [J]. ENDOCRINE REVIEWS, 1987, 8 (04) : 391 - 405
  • [7] BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO
  • [8] 2-K
  • [9] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer
    Burke, W
    Petersen, G
    Lynch, P
    Botkin, J
    Daly, M
    Garber, J
    Kahn, MJE
    McTiernan, A
    Offit, K
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11): : 915 - 919
  • [10] CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041